Multiple sclerosis care becomes inequitable early if women are offered lower-intensity disease-modifying therapy or slower escalation. Apply the same disease-activity thresholds regardless of sex, and when treatment pauses for pregnancy, document a restart date and early follow-up so high-efficacy therapy is not delayed without reason.

Hearing aid counselling in older adults should stay precise: the reported association is a possible reduction in dementia risk over seven years, not prevention. The revision point is to link hearing impairment management with cognition while avoiding claims that overstate the evidence.

Emerging migraine therapy is moving beyond CGRP, but trial signals still need disciplined interpretation. A useful bedside lesson is to document cranial autonomic symptoms and prior CGRP response carefully, because new peptide targets may help selected patients without yet replacing established treatments.

Temporary telehealth extensions are not a safe continuity plan. In neurology, delayed follow-up and prior-authorisation barriers should be treated as patient safety problems, so clinicians need to identify when reimbursement or legislation, not disease complexity, is driving missed reviews and fragmented care.

Refractory migraine is not simply frequent headache. Confirm migraine rather than another diagnosis, document burden and monthly migraine days, and remember treatment only counts as failed if benefit stays below 50%, adverse effects are intolerable, or the drug is contraindicated.

Adjunct dexamethasone should not be assumed to improve confirmed HSV encephalitis simply because it appears safe. In this phase III trial, 26-week outcomes, mortality, and discharge timing were similar to acyclovir alone, and the findings should not be extrapolated to undifferentiated encephalitis.

‍